Pioglitazone and Losartan Provides Additional Renoprotection

Shanghai Jiao Tong University School of Medicine

Status: Completed

Conditions: Diabetic Nephropathy; Type 2 Diabetes

Treatments: Drug: pioglitazone+losartan; Drug: losartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00364988

PLAN

Details and patient eligibility

About

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Enrollment: 60 patients

Sex: All

Ages: 32 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
• 2h plasma glucose level of 7.5-13 mmol/L
• serum creatinine values between 190 and 660umol/L
• Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is >150mg
• Informed consent

Exclusion criteria

• Type1 diabetes or nondiabetic renal disease
• abnormal liver function
• heart dysfunction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)